2022 HNSCC Symposium Poster: Phase 1/2 study of pepinemab in combination with pembrolizumab as first-line treatment of advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)
2022 CHDI poster: Combination anti-SEMA4D immunotherapy and HTT-lowering ASO provide benefit beyond either individual therapy in preclinical HD mouse model
American Academy of Neurology 2022 Annual Meeting Poster: Clinical evidence that treatment with pepinemab, a novel regulator of neuroinflammation, may provide cognitive benefit to patients with Huntington’s and potentially other neurodegenerative diseases
AACR Annual Meeting 2022 poster: Phase 1/2 study of pepinemab with pembrolizumab for first-line treatment of R/M Head and Neck Cancer
AACR Annual Meeting 2022 poster: Phase 1/2 study of pepinemab with pembrolizumab for first-line treatment of R/M Head and Neck Cancer
PEGS Boston 2022. Native complex membrane antigen expression on poxvirus for antibody discovery
PEGS Boston 2022. Native complex membrane antigen expression on poxvirus for antibody discovery